

Press release
Gothenburg, Sweden
February 28, 2022, at 08:00 (CET)



BICO Group AB (publ) announces an increase in number of shares and votes

The number of shares and votes in BICO Group AB (publ) ("BICO") have increased following the exercise of 756,000 warrants pursuant to BICO's warrant programme 2018 for subscription of 756,000 shares of series B.

As of February 28, 2022, the total number of registered and outstanding shares of BICO amounts to 64,086,269 of which 1,500,000 are shares of series A, corresponding to a total of 15,000,000 votes and 62,586,269 are shares of series B, corresponding to a total of 62,586,269 votes. Consequently, the total number of votes for the two classes of shares amounts to 77,586,269. The share capital amounts to SEK 1,602,156.725. The company does not hold any treasury shares.

For further information, please contact:

Isabelle Ljunggren, Head of Communications BICO
Phone: +46 708 30 08 90
Email: il@bico.com

This is information that BICO Group AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on February 28, 2022, at 08:00 a.m. (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO's technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 10,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com